Ibex Medical Analytics announced today that it appointed Dr. Douglas Clark as its new chief medical officer.
In addition to appointing Clark to its executive team, Ibex announced that co-founder & CEO Joseph Mossel will relocate to the U.S. to lead its North American expansion efforts from its Boston headquarters.
Clark previously served as CMO at TriCore, having recorded tenures as a physician, professor of pathology and senior executive across his career. He was the chair of the pathology department at the University of New Mexico School of Medicine and a professor of pathology and oncology at The Johns Hopkins Medical Institutions.
“I am very excited to join the Ibex team and work closely with physicians and providers as they enhance the quality of cancer diagnosis with Ibex’s strong AI,” Clark said in a news release. “My entire career has been dedicated to driving innovation in the pathology laboratory and improving patient care. Ibex’s AI technology enables the next transformation in cancer diagnosis and I am eager to help accelerate that transition.”
Tel Aviv, Israel–based Ibex uses AI and machine learning technology to power its Galen platform for cancer diagnostics based on hundreds of thousands of image samples scanned from biopsy slides through digital pathology. Galen won CE mark earlier this year.
“We are very proud to welcome Dr. Clark to our executive leadership team. Doug brings a wealth of clinical experience, deep understanding of the cancer pathway and invaluable knowledge about the U.S. healthcare system,” Mossel said. “2021 is a transformative year for AI-powered cancer diagnostics, and I am thrilled with the pace at which our business in the Americas is growing. I look forward to working with Dr. Clark and our commercial leader Joel Duckworth and continue to rapidly expand the Ibex footprint across the country.”
